What is Leerink Partnrs’ Estimate for MDGL Q2 Earnings?
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) – Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for Madrigal Pharmaceuticals in a research note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst T. Smith forecasts that the biopharmaceutical company will post earnings of ($2.59) per share for the […]
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) – Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for Madrigal Pharmaceuticals in a research note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst T. Smith forecasts that the biopharmaceutical company will post earnings of ($2.59) per share for the […]
